{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adriamycin%2FCytoxan", "query": { "intervention": "Adriamycin/Cytoxan" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 762, "total_pages": 77, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adriamycin%2FCytoxan&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T06:06:37.145Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01445535", "title": "Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "T-Cell Peripheral Lymphoma", "Gamma Delta Hepatosplenic T-Cell Lymphoma", "Subcutaneous Panniculitis-Like T-Cell Lymphoma", "NK T-Cell Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Siplizumab", "type": "BIOLOGICAL" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 15, "start_date": "2009-01-13", "completion_date": "2020-10-22", "has_results": true, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-09-29T06:06:37.145Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01445535" }, { "nct_id": "NCT00217425", "title": "Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2006-09-14", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2023-06-18", "last_synced_at": "2026-09-29T06:06:37.145Z", "location_count": 110, "location_summary": "Greenbrae, California • Palo Alto, California • Fort Collins, Colorado + 77 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Aurora", "state": "Illinois" }, { "city": "Bloomington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00217425" }, { "nct_id": "NCT00189137", "title": "Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma, Soft Tissue" ], "interventions": [ { "name": "ifosfamide and doxorubicin vs gemcitabine and docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 84, "start_date": "2004-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2015-12-07", "last_synced_at": "2026-09-29T06:06:37.145Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00189137" }, { "nct_id": "NCT00877006", "title": "Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "bendamustine", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 447, "start_date": "2009-04-30", "completion_date": "2012-03-31", "has_results": true, "last_update_posted_date": "2018-02-05", "last_synced_at": "2026-09-29T06:06:37.145Z", "location_count": 79, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Corona, California + 70 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00877006" }, { "nct_id": "NCT00074139", "title": "Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Advanced Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "FEMALE", "summary": "18 Years to 69 Years · Female only" }, "enrollment_count": 0, "start_date": "2003-09", "completion_date": "2003-12", "has_results": false, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-09-29T06:06:37.145Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074139" }, { "nct_id": "NCT00136539", "title": "Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Herceptin", "type": "DRUG" }, { "name": "Taxol", "type": "DRUG" }, { "name": "Adriamycin", "type": "DRUG" }, { "name": "Cytoxan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Harold J. Burstein, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "1999-03", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2013-02-18", "last_synced_at": "2026-09-29T06:06:37.145Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00136539" }, { "nct_id": "NCT00148681", "title": "Preoperative Herceptin and Navelbine for Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Stage II Breast Cancer", "Stage III Breast Cancer" ], "interventions": [ { "name": "Herceptin", "type": "DRUG" }, { "name": "Navelbine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2001-05", "completion_date": "2003-05", "has_results": false, "last_update_posted_date": "2019-01-15", "last_synced_at": "2026-09-29T06:06:37.145Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00148681" }, { "nct_id": "NCT02228772", "title": "Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Lymphoblastic Lymphoma", "B-cell Adult Acute Lymphoblastic Leukemia", "T-cell Adult Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "MLN 9708", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "51 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "51 Years to 75 Years" }, "enrollment_count": 19, "start_date": "2014-12", "completion_date": "2019-11", "has_results": false, "last_update_posted_date": "2019-11-26", "last_synced_at": "2026-09-29T06:06:37.145Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02228772" }, { "nct_id": "NCT00022230", "title": "Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Roger Williams Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2000-01", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2015-05-05", "last_synced_at": "2026-09-29T06:06:37.145Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022230" }, { "nct_id": "NCT01313884", "title": "Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bone Cancer", "Ewing's Sarcoma" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 3, "start_date": "2011-05", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2017-11-24", "last_synced_at": "2026-09-29T06:06:37.145Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01313884" } ] }